24/7 Market News Snapshot 07 October, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

October 7, 2025

DENVER, Colo., 07 October, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
BioAffinity Technologies, Inc. has recently captured significant attention in the financial markets, with its stock, BIAF, demonstrating a dramatic surge of 53.28% as trading volumes reached approximately 1.53 million shares. This increase in valuation, with shares trading at $3.92, highlights a growing investor interest and indicates strong bullish momentum for the company. Analysts suggest that this notable price action could be indicative of sustained growth.

Moreover, the company has reported unprecedented sales growth for its cutting-edge diagnostic test, CyPath® Lung. In the third quarter of 2025, sales surged by 95% compared to the previous quarter, driven primarily by heightened adoption rates among healthcare providers, particularly within Veterans’ hospitals. This substantial uptick reflects a firm confidence in the product’s efficacy in detecting lung cancer at its most treatable stages. Maria Zannes, President and CEO, noted the significance of this growth, emphasizing the test’s ability to spare patients from unnecessary invasive procedures while reaffirming market confidence.

The metrics are compelling, showing a 77% increase in the number of new patients utilizing CyPath® Lung over just one quarter. Published case studies have also illustrated the test’s critical role in the early detection of lung cancer, demonstrating its effectiveness in identifying Stage 1A cases that might have previously gone undiagnosed.

Dr. Gordon Downie, Chief Medical Officer, highlighted the transformative potential of CyPath® Lung, reaffirming its importance in early detection and reduced invasive procedures, which ultimately benefit patient well-being. Utilized through advanced flow cytometry and artificial intelligence, CyPath® Lung has achieved an impressive sensitivity rate of 92% for lung cancer detection. As BioAffinity Technologies further develops its marketing and sales strategies, the innovative CyPath® Lung test is set to reshape the diagnostic landscape for lung cancer management, promising enhanced outcomes and vital improvements in patient care.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.